Skip Navigation
Search Menu
Find an Expert

 


Daniel W. Chan, Ph.D.

Photo of Dr. Daniel W. Chan, Ph.D.

Professor of Pathology

Research Interests: Immunoassay; Biochemical Tumor Markers - Particularly Breast and Prostate Tumor Makers; Clinical Chemistry; Proteomics

Background

Daniel W. Chan, Ph.D., DABCC, FACB (2016)

Dr. Daniel W. Chan is Professor of Pathology, Oncology, Radiology and Urology, the Director of Center for Biomarker Discovery and Translation at the Johns Hopkins University. He is also the Director of Clinical Chemistry Division and the Co-Director of Pathology Core Laboratory at the Johns Hopkins Hospital, Baltimore, Maryland, USA.

Dr. Chan is a diplomat of the American Board of Clinical Chemistry (ABCC) and a fellow of the National Academy of Clinical Biochemistry (NACB). He is an internationally recognized expert in cancer biomarkers, clinical proteomics and molecular diagnostics.  He has written 5 books, 40 book chapters and 300 scientific articles. He is funded by the National Cancer Institute (NCI) as the Principal investigator of the CPTAC (Cancer Proteomic Tumor Analysis Consortium) and the Biomarker Reference Lab for the EDRN (Early Detection Research Network).

The focus of Dr. Chan's research is the development and application of proteomic and immunologic techniques in the diagnosis, management, and understanding of cancer. He is an internationally recognized expert in immunoassay, clinical proteomics, and biochemical tumor markers, particularly prostate, and ovarian cancer biomarkers. In 1977, he conducted the clinical study of CA27.29 as a marker for breast cancer recurrence leading to the 1st FDA approval of a
serum breast cancer assay. In 2000, he founded the Center for Biomarker Discovery and Translation. The focus of this Center is the discovery of proteomics biomarkers using mass spectrometry and protein microarrays, followed by the validation and translation of these novel biomarkers for the detection, diagnosis, classification, management and understanding of human diseases.  In 2009, he developed the OVA1 test for ovarian cancer – the 1st FDA cleared proteomic in vitro diagnostic multivariate index assay (IVDMIA). In 2012, he developed public-private partnerships (NCI EDRN, industry and academic centers) leading to the clinical study, publication and FDA approval of new prostate cancer tests – proPSA (phi) with Beckman Coulter Inc. and PCA3 (PROGENSA) with Gen-probe (Hologic, Inc).

Dr. Chan has trained over 20 clinical chemistry fellows at Johns Hopkins. Many of these scientists have become leaders and professor in Clinical Chemistry. During the last 20 years, he has given over two hundred invited lectures, both within and outside of US.   

Dr. Chan received numerous awards for his outstanding contributions to clinical chemistry. Examples are the inaugural Morton K. Schwartz Award for Cancer Research Diagnostics, Albert Nichols Award for strategic innovation in laboratory medicine, Norman Kubasik Award for Outstanding contribution to the education of clinical laboratory scientists, Bernard Gerulat Award for outstanding achievement in clinical chemistry, Carl R. Joliff Award for Outstanding achievement in diagnostic immunology and education, Miriam Reiner Award for outstanding contributions to research in the field of clinical chemistry and Outstanding Contribution to Clinical Chemistry in Research Award (all from the AACC). Outstanding Leadership Award (NCI-EDRN), inaugural Translational Proteomics Award (HUPO). He served as the Chair of the Proteomics Division (a founder) of the American Association for Clinical Chemistry (AACC), Board of Directors of NACB and as the President of the National Registry in Clinical Chemistry (NRCC), President of the International Society of Enzymology (ISE) and on the Board of Directors (a founder) of the US Human Proteome Organization (HUPO). He is the Editor-in-Chief of the journal Clinical Proteomics.

...read more

Titles

  • Professor of Pathology
  • Professor of Oncology
  • Professor of Radiology and Radiological Science
  • Professor of Urology

Departments / Divisions

Research & Publications

Research Summary

The focus of Dr. Chan's research is the development and application of proteomic and immunologic techniques in the diagnosis, management, and understanding of cancer. His work has demonstrated the importance of analytical methodologies for tumor markers, endocrine or clinical chemistry assays to determine the clinical outcomes of a patient?s disease process.

He is an internationally recognized expert in immunoassay, clinical proteomics, and biochemical tumor markers, particularly prostate, breast and ovarian cancer biomarkers.

He has edited and written five books on immunoassay, immunoassay automation, diagnostic endocrinology, and tumor markers. Dr. Chan has published over 200 articles including the tumor markers chapters in the Tietz Textbook of Clinical Chemistry and in Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications, which he also co-edited.

Dr. Chan is actively involved in the Human Proteome Organization (HUPO) and its Plasma Proteome Initiative. He serves as chairman of a HUPO committee responsible for the development of reference specimens for a global comprehensive study of the human proteome.

Selected Publications

  1. Li, Y.; Tian, Y.; Rezai, T.; Prakash, A.; Lopez, M.F.; Chan, D.W.; Zhang, H. Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues. Anal Chem. 2011 Jan 1;83(1):240-245.
  2. Sokoll, L.J.; Sanda, M.G.; Feng, Z.; Kagan, J.; Mizrahi, I.A.; Broyles, D.L.; Partin, A.W.; Srivastava, S.; Thompson, I.M.; Wei, J.T.; Zhang, Z.; Chan, D.W. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1193-1200.
  3. Zhou, J.; Trock, B.; Tsangaris, T.N.; Friedman, N.B.; Shapiro, D.; Brotzman, M.; Chan-Li, Y.; Chan, D.W.; Li, J. A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient. Breast Cancer Res Treat. 2009 Nov 10.
  4. Rosenzweig, C.N.; Zhang, Z.; Sun, X.; Sokoll, L.J.; Osborne, K.; Partin, A.W.; Chan, D.W. Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J Urol. 2009 Mar;181(3):1407-1414.
  5. Rosenzweig, C.N., Zhang, Z., Sun, X., Sokoll, L.J., Osborne, K., Partin, A.W., and Chan, D.W. Predicition of biochemcial recurrence of prostate cancer using a panel of serum proteomic biomarkers. J Urol. 2009;181(3):1407-1414.
  6. Meany, D.L.; Zhang, Z.; Sokoll, L.J.; Zhang, H.; Chan, D.W. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. J Proteome Res. 2009 Feb;8(2):613-619.
  7. Meany, D.L.; Sokoll, L.J.; Chan, D.W. Early Detection of Cancer: Immunoassays for Plasma Tumor Markers. Expert Opin Med Diagn. 2009 Nov 1;3(6):597-605.
  8. Loeb, S.; Schaeffer, E.M.; Chan, D.W.; Carter, H.B.; Walsh, P.C.; Sokoll, L.J. Investigation of human anti-mouse antibodies as potential cause of postprostatectomy PSA elevation. Urology. 2009 May;73(5):947-949.
  9. Fujita, K.; Ewing, C.M.; Chan, D.Y.; Mangold, L.A.; Partin, A.W.; Isaacs, W.B.; Pavlovich, C.P. Endoglin (CD105) as a urinary and serum marker of prostate cancer. Int J Cancer. 2009 Feb 1;124(3):664-669.
  10. Sturgeon, C.M.; Duffy, M.J.; Stenman, U.H.; Lilja, H.; Brunner, N.; Chan, D.W.; Babaian, R.; Bast, R.C., Jr.; Dowell, B.; Esteva, F.J.; Haglund, C.; Harbeck, N.; Hayes, D.F.; Holten-Andersen, M.; Klee, G.G.; Lamerz, R.; Looijenga, L.H.; Molina, R.; Nielsen, H.J.; Rittenhouse, H.; Semjonow, A.; Shih Ie, M.; Sibley, P.; Soletormos, G.; Stephan, C.; Sokoll, L.; Hoffman, B.R.; Diamandis, E.P. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008 Dec;54(12):e11-79.

Füzéry AK, Levin J, Chan MM and Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics 2013, 10:13.

Sartori DA and Chan DW. Biomarkers in prostate cancer: what's new? Curr Opin Oncol 2014, 26(3): 259-64.

Li, D and Chan DW. Proteomic cancer biomarkers from discovery to approval: it's worth the effort. Expert Rev Proteomics 2014, 11(2):135-6.

Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers. Li QK, Chen L, Ao MH, Chiu JH, Zhang Z, Zhang H, Chan DW. Theranostics. 2015 Jan 1;5(3):267-76

Natural history of progression after PSA elevation following radical prostatectomy CR Pound, AW Partin, MA Eisenberger, DW Chan, JD Pearson, PC Walsh JAMA 281 (17), 1591-1597, 1999.

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
HB Carter, JD Pearson, EJ Metter, LJ Brant, DW Chan, R Andres, ...JAMA 267 (16), 2215-2220, 1992.

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. AW Partin, J Yoo, HB Carter, JD Pearson, DW Chan, JI Epstein, PC Walsh The Journal of urology 150 (1), 110-114, 1993.

Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer
J Li, Z Zhang, J Rosenzweig, YY Wang, DW Chan. Clinical chemistry 48 (8), 1296-1304, 2002.

Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Z Zhang, RC Bast, Y Yu, J Li, LJ Sokoll, AJ Rai, JM Rosenzweig, ...DW Chan
Cancer research 64 (16), 5882-5890, 2004.

Is this you? Edit Profile